Belantamab Induces Deep Responses in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma.
- Published in:
- Value-Based Cancer Care, 2021, v. 12, n. 1, p. 22
- By:
- Publication type:
- Article
Works matching IS 21534888 AND DT 2021 AND VI 12 AND IP 1
Results: 26
1
2
Bispecific Antibodies in Phase 1 Studies Show Promising Efficacy in Heavily Pretreated Patients with Multiple Myeloma.
- Published in:
- Value-Based Cancer Care, 2021, v. 12, n. 1, p. 21
- By:
- Publication type:
- Article
3
Pembrolizumab Shows Long-Term Benefits in Metastatic Colorectal Cancer and MSI-H or dMMR.
- Published in:
- Value-Based Cancer Care, 2021, v. 12, n. 1, p. 20
- Publication type:
- Article
4
ZUMA-12: Axicabtagene Ciloleucel Shows Substantial Benefit in High-Risk Large B-Cell Lymphoma.
- Published in:
- Value-Based Cancer Care, 2021, v. 12, n. 1, p. 20
- By:
- Publication type:
- Article
5
Sitagliptin, DPP-4 Inhibitor, Reduces the Incidence of Acute GVHD After Stem-Cell Transplant.
- Published in:
- Value-Based Cancer Care, 2021, v. 12, n. 1, p. 19
- Publication type:
- Article
6
Step-Up Glofitamab Dosing Induces High Response Rates in Relapsed or Refractory Non-Hodgkin Lymphoma.
- Published in:
- Value-Based Cancer Care, 2021, v. 12, n. 1, p. 19
- By:
- Publication type:
- Article
7
Momelotinib, a Novel JAK Inhibitor, Makes Inroads in Intermediate- or High-Risk Myelofibrosis.
- Published in:
- Value-Based Cancer Care, 2021, v. 12, n. 1, p. 18
- By:
- Publication type:
- Article
8
Emerging Molecular Targets in Cholangiocarcinoma: IDH1, HER2, BRAF, and Beyond.
- Published in:
- Value-Based Cancer Care, 2021, v. 12, n. 1, p. 17
- Publication type:
- Article
9
Targeted Therapies in Cholangiocarcinoma.
- Published in:
- Value-Based Cancer Care, 2021, v. 12, n. 1, p. 17
- Publication type:
- Article
10
Umbralisib plus Ublituximab Combination Superior to Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia.
- Published in:
- Value-Based Cancer Care, 2021, v. 12, n. 1, p. 16
- By:
- Publication type:
- Article
11
First-Line Fixed-Duration Ibrutinib plus Venetoclax Therapy Leads to Deep Remissions in Patients with Chronic Lymphocytic Leukemia.
- Published in:
- Value-Based Cancer Care, 2021, v. 12, n. 1, p. 15
- By:
- Publication type:
- Article
12
Oral Azacitidine Extends Survival in Acute Myeloid Leukemia, Regardless of MRD Status, in Patients in Remission After Chemotherapy .
- Published in:
- Value-Based Cancer Care, 2021, v. 12, n. 1, p. 14
- By:
- Publication type:
- Article
13
Novel Target: RARA Agonist plus Azacitidine Active in Relapsed or Refractory Acute Myeloid Leukemia.
- Published in:
- Value-Based Cancer Care, 2021, v. 12, n. 1, p. 12
- By:
- Publication type:
- Article
14
Tagrisso Approved as Adjuvant Therapy for NSCLC with EGFR Mutations.
- Published in:
- Value-Based Cancer Care, 2021, v. 12, n. 1, p. 11
- Publication type:
- Article
15
Magrolimab, First CD47 Antibody Shows Promise in Combination with Azacitidine in Unfit Patients with Acute Myeloid Leukemia.
- Published in:
- Value-Based Cancer Care, 2021, v. 12, n. 1, p. 11
- By:
- Publication type:
- Article
16
Xalkori Approved for Anaplastic Large-Cell Lymphoma and ALK Mutation in Young Patients.
- Published in:
- Value-Based Cancer Care, 2021, v. 12, n. 1, p. 10
- Publication type:
- Article
17
Oral Vodobatinib Elicits Durable Responses in Heavily Pretreated Patients with Chronic Myeloid Leukemia.
- Published in:
- Value-Based Cancer Care, 2021, v. 12, n. 1, p. 10
- By:
- Publication type:
- Article
18
FDA Approves Margenza for Treatment of Metastatic HER2-Positive Breast Cancer.
- Published in:
- Value-Based Cancer Care, 2021, v. 12, n. 1, p. 9
- Publication type:
- Article
19
Pevonedistat plus Azacitidine Combination Improves Outcomes versus Azacitidine Monotherapy in HighRisk Myelodysplastic Syndromes .
- Published in:
- Value-Based Cancer Care, 2021, v. 12, n. 1, p. 8
- By:
- Publication type:
- Article
20
Orgovyx First FDA-Approved Oral Hormone Therapy for Advanced Prostate Cancer.
- Published in:
- Value-Based Cancer Care, 2021, v. 12, n. 1, p. 7
- Publication type:
- Article
21
Financial Toxicity Intervention in Patients with Hematologic Malignancies Effective, Improves Adherence and Quality of Life.
- Published in:
- Value-Based Cancer Care, 2021, v. 12, n. 1, p. 6
- By:
- Publication type:
- Article
22
FDA Approves Tepmetko for Metastatic NSCLC and MET Exon 14 Skipping Alterations.
- Published in:
- Value-Based Cancer Care, 2021, v. 12, n. 1, p. 5
- Publication type:
- Article
23
First-Line Mosunetuzumab Safe and Effective in Older Patients with Diffuse Large B-Cell Lymphoma.
- Published in:
- Value-Based Cancer Care, 2021, v. 12, n. 1, p. 1
- By:
- Publication type:
- Article
24
Asciminib, First-in-Class STAMP Inhibitor, Superior to Bosutinib in Chronic-Phase CML.
- Published in:
- Value-Based Cancer Care, 2021, v. 12, n. 1, p. 1
- By:
- Publication type:
- Article
25
Ruxolitinib in Graft-versus-Host Disease: Practice-Changing Results.
- Published in:
- Value-Based Cancer Care, 2021, v. 12, n. 1, p. 1
- By:
- Publication type:
- Article
26
ASH 2020 Presidential Symposium Highlights Innovations Aimed to Improve Patient Access to Treatment.
- Published in:
- Value-Based Cancer Care, 2021, v. 12, n. 1, p. 1
- By:
- Publication type:
- Article